| 摘要: |
| 随着人们对肿瘤研究的深入,肿瘤疗法也越来越多元化,免疫疗法逐渐成为研究的热点。嵌合抗原受体T细胞疗法(Chimeric Antigen Receptor T cell,CAR-T)是当今肿瘤治疗领域最具研究前景的方向之一,在血液瘤治疗方面取得了重大突破,但在实体瘤中一直未有突破。本文就CAR-T的结构发展历程和在实体瘤治疗中遇到的困难展开讨论。 |
| 关键词: 嵌合抗原受体T细胞疗法 发展历程 实体瘤 困难 |
| DOI:10.13506/j.cnki.jpr.2020.09.008 |
| 基金项目:国家自然基金青年基金项目(No.81903656) |
|
|
|
| Development of CAR-T and difficulties in the treatment of solid tumor |
| MA Jinyan,YANG Yong,WANG Yun |
| (Institute of Pharmaceutical Science,China Pharmaceutical University,Nanjing 211198,China) |
| Abstract: |
| With the development of tumor research, novel therapies have occurred, including immunotherapy. One of the most promising therapies is Chimeric Antigen Receptor T cell therapy (CAR-T). It has achieved the great breakthroughs in the treatment of hematological malignancy, but not in solid tumor. This article discussed the development of CAR-T and the difficulties encountered in the treatment of solid tumor. |
| Key words: CAR-T Development Solid tumor Difficulties |